Perivascular Epithelioid Cell Tumor (PEComa): Rare Imaging Diagnosis, CT Findings, and Modern Treatment Guide

 


Perivascular Epithelioid Cell Tumor (PEComa): The Rare Tumor Every Radiologist Should Recognize

Imagine a young patient arriving in the emergency department with nothing more alarming than a fever and a cough. A routine chest X-ray is performed. Instead of pneumonia alone, the radiologist discovers a large thoracic mass. Further CT imaging reveals a second renal lesion. Biopsy later confirms an exceptionally rare diagnosis: Perivascular Epithelioid Cell Tumor (PEComa).

This scenario illustrates why PEComa matters in modern medical imaging, CT scan diagnosis, and radiology interpretation. Though uncommon, PEComa can mimic more common malignancies and may appear in the kidney, liver, mediastinum, uterus, lung, retroperitoneum, and soft tissues.

For clinicians, radiologists, oncologists, and informed readers, understanding PEComa is increasingly important because targeted therapy using mTOR inhibitors has transformed treatment in selected patients.


What Is Perivascular Epithelioid Cell Tumor (PEComa)?

PEComa is a rare mesenchymal neoplasm composed of perivascular epithelioid cells, a unique cell type showing both melanocytic and smooth muscle differentiation.

The PEComa family includes:

  • Angiomyolipoma (AML)
  • Lymphangioleiomyomatosis (LAM)
  • Clear-cell “sugar” tumor of the lung
  • Epithelioid angiomyolipoma
  • Soft tissue / visceral PEComa NOS (not otherwise specified)

PEComas may be benign, locally aggressive, or frankly malignant.


Why PEComa Is Important in Medical Imaging

PEComa often presents as a mass with non-specific radiologic findings. That means it can resemble:

  • Renal cell carcinoma
  • Sarcoma
  • Lymphoma
  • Metastatic disease
  • Adrenal tumors
  • Thymic masses
  • Germ cell tumors

Because imaging findings overlap with dangerous conditions, correct diagnosis often requires combining:

  • Clinical history
  • CT scan patterns
  • MRI findings
  • Histopathology
  • Immunohistochemistry

Pathophysiology

PEComa biology is closely linked to the TSC1 and TSC2 tumor suppressor genes.

These genes regulate the mTOR signaling pathway, which controls:

  • Cell growth
  • Protein synthesis
  • Metabolism
  • Proliferation
  • Autophagy

When TSC1/TSC2 are inactivated, uncontrolled mTOR activation may drive tumor growth.

𝑚𝑇𝑂𝑅𝐶𝑒𝑙𝑙 𝐺𝑟𝑜𝑤𝑡

This explains why sirolimus and everolimus can shrink many PEComas.


Epidemiology

PEComa is rare worldwide.

Key Facts

  • More common in adults than in children
  • Female predominance in many subtypes
  • Pediatric cases are exceptionally uncommon
  • Strong association with Tuberous Sclerosis Complex
  • Can occur in nearly any organ system

Because of rarity, many cases are initially misdiagnosed.


Clinical Presentation

Symptoms depend on location.

Renal PEComa

  • Flank pain
  • Hematuria
  • Incidental mass on CT
  • Abdominal fullness

Mediastinal PEComa

  • Cough
  • Chest pain
  • Dyspnea
  • Incidental chest X-ray finding

Uterine / Pelvic PEComa

  • Bleeding
  • Pelvic pain
  • Pressure symptoms

Emergency Diagnosis Context

Some lesions are discovered unexpectedly during imaging for unrelated symptoms—an increasingly common scenario in modern healthcare.


Imaging Features: CT, MRI, Ultrasound, X-Ray

Chest X-Ray Findings

Figure 1. Chest X-ray Demonstrating Thoracic Mass

From the uploaded case report, the chest radiograph showed:

  • Large right lower hemithorax mass
  • Broad mediastinal attachment
  • Right paratracheal stripe thickening

Radiologic interpretation: Suggests mediastinal-origin soft tissue mass requiring urgent CT characterization.


Ultrasound Findings

Figure 2. Left Renal Exophytic Mass on Ultrasound

  • Solid exophytic lesion from the lower pole of the left kidney
  • Multiple cortical echogenic foci consistent with angiomyolipomas

Diagnostic value: Ultrasound identifies renal origin but lacks specificity.


CT Scan Diagnosis: Most Important Tool

Figure 3. Contrast CT Chest

  • Well-defined anterior mediastinal mass
  • Inseparable from the right cardiac border
  • Associated compressive atelectasis

Figure 4. Contrast CT Abdomen

  • Lobulated exophytic left renal mass
  • Similar attenuation to the mediastinal lesion
  • Mild mass effect on the renal vein
  • No visible macroscopic fat
  • No calcification or cystic degeneration

Why this matters: Similar enhancement patterns in two separate lesions strongly suggested synchronous pathology.


Typical CT Characteristics of PEComa

FeatureCommon Finding
Margin     Well circumscribed
Density     Soft tissue attenuation
Enhancement     Moderate to strong heterogeneous enhancement
Fat     May be absent in the epithelioid subtype
Necrosis     Possible in aggressive tumors
Calcification     Uncommon
Invasion     Suggests malignancy

MRI Findings

MRI may show:

  • T1 iso- to hypointense mass
  • T2 variable hyperintensity
  • Strong post-contrast enhancement
  • Restricted diffusion in cellular tumors
  • Better local staging than CT

MRI is especially valuable in pelvic, hepatic, and soft tissue PEComa.


Differential Diagnosis

Because PEComa is rare, the differential diagnosis is broad.

Kidney Mass Differential

  • Renal Cell Carcinoma
  • Fat-poor angiomyolipoma
  • Lymphoma
  • Wilms tumor (children)
  • Metastasis

Mediastinal Mass Differential

  • Thymoma
  • Lymphoma
  • Germ cell tumor
  • Sarcoma
  • Metastatic disease

Diagnosis Workflow

Step 1: Detect Mass on Imaging

Usually X-ray, ultrasound, CT, or MRI.

Step 2: Evaluate Enhancement Pattern

Look for a hypervascular soft tissue lesion.

Step 3: Assess Fat Content

Classic AML contains fat; epithelioid lesions often do not.

Step 4: Consider Syndromic History

Especially Tuberous Sclerosis Complex.

Step 5: Tissue Diagnosis

Immunohistochemistry is typically positive for:

  • HMB-45
  • Melan-A
  • SMA
  • Desmin (variable)

Step 6: Risk Stratification

Size, necrosis, mitoses, invasion, and recurrence risk.


Treatment

Surgery

Preferred for:

  • Localized tumors
  • Symptomatic masses
  • Suspicious malignant lesions
  • Resectable disease

Targeted Therapy (mTOR Inhibitors)

Most important recent advance:

  • Sirolimus
  • Everolimus

These drugs can significantly reduce tumor burden, especially in TSC-associated disease.

Figure 5. Follow-Up Imaging

The uploaded case showed marked reduction in mediastinal and renal masses after approximately 2 years of sirolimus therapy.

Other Options

  • Embolization (selected renal lesions)
  • Systemic therapy in advanced disease
  • Surveillance in indolent cases

Prognosis

Prognosis varies widely.

Favorable Factors

  • Small size
  • Well-circumscribed lesion
  • No necrosis
  • Low mitotic activity
  • No invasion

Concerning Factors

  • Tumor >5 cm
  • Necrosis
  • Infiltrative margins
  • Vascular invasion
  • High-grade atypia
  • Metastasis

Some malignant PEComas behave aggressively.


Key Takeaways

  • PEComa is a rare mesenchymal tumor with variable behavior.
  • CT imaging is central for detection and staging.
  • Absence of fat does not exclude AML-spectrum tumors.
  • Tuberous sclerosis history is a major clue.
  • Biopsy with immunohistochemistry confirms the diagnosis.
  • mTOR inhibitors can dramatically improve outcomes.

FAQ

Is PEComa cancer?

Some PEComas are benign, while others are malignant. Risk depends on size, invasion, necrosis, and histology.

Can a CT scan diagnose PEComa alone?

No. CT strongly suggests the lesion, but pathology is usually required.

Is PEComa hereditary?

Some cases are associated with Tuberous Sclerosis Complex.

What is the best treatment?

Localized tumors are often resected. TSC-associated or unresectable lesions may respond to mTOR inhibitors.


Quiz

1. Which pathway is most commonly implicated in PEComa biology?

A. JAK-STAT
B. MAPK
C. mTOR
D. Wnt
E. VEGF

Answer: C. Explanation: PEComa commonly involves TSC1/TSC2 dysfunction leading to mTOR activation.


2. Which imaging modality is most useful for staging PEComa?

A. Plain radiograph
B. CT scan
C. Mammography
D. DEXA
E. Fluoroscopy

Answer: B. Explanation: Contrast-enhanced CT is highly useful for lesion characterization, staging, and surgical planning.


3. Which marker commonly supports PEComa diagnosis?

A. PSA
B. HMB-45
C. CD20
D. TTF-1
E. CA-125

Answer: B. Explanation: HMB-45 positivity is characteristic of PEComa.


Recommended Reading

  1. G. Martignoni et al., “PEComas: the past, the present and the future,” Virchows Arch., 2008. DOI: https://doi.org/10.1007/s00428-007-0509-1
  2. J. L. Hornick and C. D. Fletcher, “PEComa: what do we know so far?” Histopathology, 2006. DOI: https://doi.org/10.1111/j.1365-2559.2005.02316.x
  3. S. H. Tirumani et al., “Imaging features of malignant PEComa,” AJR, 2014. DOI: https://doi.org/10.2214/AJR.13.10909
  4. M. A. Dickson et al., “PEComas respond to mTOR inhibition,” Int J Cancer, 2013. DOI: https://doi.org/10.1002/ijc.27800
  5. E. P. Henske et al., “Tuberous sclerosis complex,” Nat Rev Dis Primers, 2016. DOI: https://doi.org/10.1038/nrdp.2016.35
  6. Y. Tan et al., “Dynamic CT and MRI characteristics of PEComa,” Clin Radiol., 2013. DOI: https://doi.org/10.1016/j.crad.2012.10.021
  7. K. T. Mai and E. C. Belanger, “Soft tissue PEComa,” Pathology, 2006. DOI: https://doi.org/10.1080/00313020600922504

Comments

Popular posts from this blog

Understanding Tubal Ligation Clips: Imaging, Risks, Migration, and Management

The Lethal Lens: Mastering the Diagnosis and Management of Epidural Hemorrhage (EDH)

Teres Minor Atrophy: Causes, Imaging, and Clinical Implications